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Aquaporin-3 potentiates allergic 
airway inflammation in ovalbumin-
induced murine asthma
Kohei Ikezoe1, Toru Oga2, Tetsuya Honda3,4, Mariko Hara-Chikuma3,4, Xiaojun Ma5, 
Tatsuaki Tsuruyama6, Kazuko Uno7, Jun-ichi Fuchikami8, Kiminobu Tanizawa2, 
Tomohiro Handa1, Yoshio Taguchi9, Alan S. Verkman10, Shuh Narumiya4, Michiaki Mishima1 & 
Kazuo Chin2
Oxidative stress plays a pivotal role in the pathogenesis of asthma. Aquaporin-3 (AQP3) is a small 
transmembrane water/glycerol channel that may facilitate the membrane uptake of hydrogen 
peroxide (H2O2). Here we report that AQP3 potentiates ovalbumin (OVA)-induced murine asthma by 
mediating both chemokine production from alveolar macrophages and T cell trafficking. AQP3 deficient 
(AQP3−/−) mice exhibited significantly reduced airway inflammation compared to wild-type mice. 
Adoptive transfer experiments showed reduced airway eosinophilic inflammation in mice receiving 
OVA-sensitized splenocytes from AQP3−/− mice compared with wild-type mice after OVA challenge, 
consistently with fewer CD4+ T cells from AQP3−/− mice migrating to the lung than from wild-type 
mice. Additionally, in vivo and vitro experiments indicated that AQP3 induced the production of some 
chemokines such as CCL24 and CCL22 through regulating the amount of cellular H2O2 in M2 polarized 
alveolar macrophages. These results imply a critical role of AQP3 in asthma, and AQP3 may be a novel 
therapeutic target.
Asthma is characterized by chronic inflammation of the airways where many cells and cellular elements are 
involved, and is associated with increased airway hyperresponsiveness (AHR). Although eosinophilic inflamma-
tion is a characteristic feature of asthma, T cells recruited into the airways orchestrate the inflammatory reaction 
through their secretion of cytokines and other mediators1. T helper type 2 (Th2) cytokines, such as interleukin 
(IL)-4 and IL-13, are involved in the class-switching of B cells to immunoglobulin E (IgE) synthesis, recruitment 
of mast cells, and maturation of eosinophils and basophils2. IL-4 and IL-13 can also induce the polarization of 
macrophages to alternatively activated macrophages (M2 macrophages). M2 macrophages are important in the 
attraction of cells to inflammatory foci, suppression of Th1 responses, sampling of the microenvironment by 
endocytosis, and orchestration of tissue repair3.
Oxidative stress plays a pivotal role in the pathogenesis of asthma. Reactive oxygen species (ROS), including 
hydrogen peroxide (H2O2), may initiate and augment airway inflammation4. ROS increase airway smooth mus-
cle contraction and stimulate mucin secretion. Many cell types, including lymphocytes and macrophages, are 
involved in the increased production of ROS in asthma. Recently, oxidative stress was suggested to be an impor-
tant factor in the development of corticosteroid insensitivity, in relation to severe asthma5.
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Aquaporins (AQPs) are small integral membrane proteins that transport water across cell plasma membranes6. 
Of these, aquaglyceroporins, including aquaporin-3 (AQP3), also transport small uncharged molecules such as 
glycerol. AQP3 is localized in various tissues, including the kidney, skin, gastrointestinal tract, and respiratory 
tract7. As to its physiological roles, AQP3 is known to be essential for the urinary-concentrating mechanism in 
the kidney, and AQP3-mediated glycerol transport is important for skin hydration8,9. Recently, AQP3 was found 
to facilitate the membrane uptake of H2O2, and influence the downstream cell signaling cascade in mammalian 
cells10. We also have reported that AQP3-mediated H2O2 uptake is essential for chemokine-dependent T cell 
migration11.
AQP3 expression was shown to be upregulated in some murine asthma models12,13, although its role remains 
unknown. We hypothesized that AQP3 would contribute to the pathogenesis of asthma by regulating the amount 
of cellular H2O2. We tested this hypothesis using AQP3 deficient (AQP3−/−) mice in an ovalbumin (OVA)-induced 
murine asthma model. Further, we then determined that AQP3 facilitated murine asthma through mediating 
chemokine production from alveolar macrophages (AMs) as well as regulating T cell trafficking.
Results
Reduced OVA-induced allergic asthma in AQP3 deficient mice. After following the procedure 
for sensitization and challenge shown in Supplementary Fig. S1a, we compared OVA-induced allergic asthma 
between AQP3−/− mice and wild-type (WT) mice by assessing airway inflammation using cell counts and lung 
sections, by evaluating airway responsiveness to methacholine, and by measuring concentrations of IgE and 
Th2 cytokines. The number of total cells as well as the numbers of eosinophils, lymphocytes, and neutrophils in 
bronchoalveolar lavage fluid (BALF) increased after OVA challenge in WT mice (Fig. 1a). However, these num-
bers were significantly reduced in AQP3−/− mice compared with WT mice. Especially, a substantial reduction 
in eosinophilia, characteristic in allergic inflammation, was observed in BALF of AQP3−/− mice. These results 
were confirmed using littermate WT control mice. The numbers of T cells, B cells, CD4+ T cells, and CD8+ T 
cells in BALF from OVA-challenged AQP3−/− mice were also fewer than those from OVA-challenged WT mice 
(Supplementary Fig. S2a). Histological examination showed infiltration of inflammatory cells in the perivascular 
and peribronchial lesions (Fig. 1b) and mucus hypersecretion in airway epithelium (Fig. 1c) in OVA-challenged 
WT mice. In contrast, there was less cellularity and hypersecretion in AQP3−/− mice after OVA challenge. Specific 
airway resistance (sRaw) to methacholine was elevated in OVA-challenged WT mice compared to non-OVA-
challenged WT mice, but the elevation was significantly lower in OVA-challenged AQP3−/− mice (Supplementary 
Fig. S2b). However, this should be interpreted with caution, as the response to methacholine in non-OVA-chal-
lenged AQP3−/− mice was so flat that OVA-challenged AQP3−/− mice might have had a flatter airway response 
due to a baseline defect not to an OVA response effect.
We measured concentrations of OVA-specific IgE in the serum and several cytokines in BALF in WT and 
AQP3−/− mice and compared the results. Serum OVA-specific IgE levels were higher in WT mice after OVA 
inhalation than before OVA inhalation, while those values in AQP3−/− mice also increased but remained lower 
than in the WT mice (Fig. 1d). In both AQP3−/− and WT groups, concentrations of Th2 cytokines, IL-4 and 
IL-13, and the Th17 cytokine, IL-17F, in BALF increased after OVA challenge (Fig. 1e). However, OVA-challenged 
AQP3−/− mice had lower concentrations than did WT mice, while the levels of interferon-γ , the hallmark Th1 
cytokine, in BALF were comparable between WT and AQP3−/− mice. Thus, the loss of AQP3 resulted in reduced 
OVA-induced asthma responses, resulting in less eosinophilic inflammation and decreased Th2 cytokine 
production.
Impaired CD4+ T cell trafficking in OVA-challenged AQP3 deficient mice. The above results sug-
gest a possibility that AQP3 is involved in allergic responses in the lung. Consistently, Aqp3 messenger RNA 
(mRNA) was detected in the lungs of WT mice by real-time reverse transcription (RT)-PCR analysis, and it was 
considered that OVA challenge to the airway might enhance its levels (Fig. 2a). Immunohistochemistry revealed 
that AQP3 was expressed strongly in some inflammatory cells and weakly in airway epithelial cells in peribron-
chovascular lesions (Fig. 2b), and in AMs in alveolar lesions (Fig. 2c). As T cells, especially CD4+ T cells, play a 
critical role in the pathogenesis of asthma, we focused on AQP3 expression in those cells. We sorted BALF cells 
in OVA-challenged WT mice into CD4+ T cells, CD8+ T cells, and B cells by Auto MACS and examined Aqp3 
mRNA levels in these cells by real-time RT-PCR. Of these, CD4+ T cells most highly expressed Aqp3 mRNA and 
B cells least expressed it after OVA challenge (Fig. 2d).
We then examined T cell proliferation and activation during the sensitization phase. Splenocytes and mes-
enteric lymph node cells from OVA-sensitized WT and AQP3−/− mice were isolated on day 21 before the OVA 
challenge and were cultured in the presence and absence of OVA. The OVA-specific T cell proliferation and IL-4/
IL-13 production were comparable between WT and AQP3−/− mice (Fig. 3a,b). These findings suggest that AQP3 
is not required for OVA-specific T cell proliferation and activation.
Next, we examined the functions of T cells during the elicitation phase by using intravenous adoptive transfer 
(Supplementary Fig. S1b). As shown in Fig. 3c, the transfer of OVA-sensitized AQP3−/− splenocytes resulted in 
reduced total inflammatory cells and eosinophils in BALF in the recipient WT and AQP3−/− mice compared 
with the results from the transfer of WT donor cells after OVA challenge. However, even though the same 
genotype-derived splenocytes were transferred, the numbers of total inflammatory cells and eosinophils in BALF 
were fewer in AQP3−/− recipient mice than in WT mice after OVA challenge. Furthermore, to assess the role 
of AQP3 in T cell trafficking in vivo, we adoptively transferred the sensitized WT or AQP3−/− splenocytes that 
were labeled with the cell-tracker dye 5-chloromethylfluorescein diacetate (CMFDA) (Supplementary Fig. S1c). 
Fewer CD4+CMFDA+ cells from AQP3−/− mice were observed in both thoracic lymph nodes and lungs than 
from WT mice (Fig. 3d). These results provide evidence that AQP3 expression plays an important role in airway 
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Figure 1. Allergic airway responses are suppressed in AQP3−/− mice. (a) Cell population analyses in BALF 
by differential cell counts from WT and AQP3−/− mice (n = 5 for each control group and n = 8 for each OVA-
challenged group) on day 28. (b,c) Lung histology. Lungs of WT (n = 5 for each group) and AQP3−/− (n = 4 for 
each group) mice were dissected on day 28 and stained with hematoxylin and eosin (b) or periodic acid-Schiff 
(c). Bars, 50 μ m. The magnified figure shows the cells in the peribronchial lesion in OVA-challenged WT mice. 
Arrow indicates eosinophil. Bars of the magnified figure, 10 μ m. (d) Serum levels of OVA-specific IgE. Serum 
concentrations of OVA-specific IgE were measured in WT (n = 5 for each group) and AQP3−/− (n = 5 for each 
group) mice on day 21 and day 28. (e) Measurements of concentrations of IL-4, IL-13, IL-17F, and IFN-γ in 
BALF collected on day 28 (n = 5 for each control group; n = 8 for each OVA-challenged group). **P < 0.01, 
*P < 0.05.
www.nature.com/scientificreports/
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inflammation through its effect on CD4+ T cell trafficking during OVA challenge to the airway, but that is only a 
partial effect and other functions of AQP3 were indicated.
Impaired chemokine production by AMs in OVA-challenged AQP3-deficient mice. We next 
focused on the possible contributions of AMs to allergic reactions through AQP3 expression since immuno-
histochemistry revealed that AQP3 was expressed in AMs (Fig. 2c). First, we examined the expression of Aqp3 
mRNA in FACS Aria-sorted AMs (F4/80+CD11c+ cells) from OVA-challenged mice by real-time RT-PCR. 
OVA challenge enhanced Aqp3 mRNA expression in AMs from WT mice (Fig. 4a). We also confirmed that 
AQP3 was expressed in AMs (F4/80+ cells) in the lungs of OVA-challenged WT mice for the double staining 
of immunohistochemistry (Fig. 4b). Previous studies showed that AM was a major source of allergen-induced 
CCL24 (eotaxin-2), which is a chemoattractant for eosinophils, in mice14–17. Therefore, we measured the levels 
of CCL24 in BALF from WT and AQP3−/− mice by ELISA and found that the levels of CCL24 in BALF signifi-
cantly increased after OVA challenge in WT mice but not in AQP3−/− mice (Fig. 4c). Moreover, OVA challenge 
also strongly enhanced Ccl24 mRNA expression in total BALF cells and AMs in WT mice, but to significantly 
lesser levels in AQP3−/− mice (Fig. 4d). These findings suggest that CCL24 production by AMs was impaired in 
OVA-challenged AQP3−/− mice.
To determine the role of AQP3 in functions of AMs during OVA-induced asthma, using microarray analysis 
we compared the gene expression profiles of AMs in WT and AQP3−/− mice before and after OVA challenge. 
We extracted and analyzed 8,458 genes, which we divided into 11 clusters on the basis of their induction pattern 
(Supplementary Fig. S3a). We focused on clusters 9 and 11 where the expression of the genes was enhanced after 
OVA challenge in WT AMs but not in AQP3−/− AMs. We performed hierarchical clustering using the genes on 
clusters 9 and 11 (2,591 genes) (Fig. 5a). It was revealed that the expressions of M2 macrophage-related genes 
such as Arg1 and Retnla (also known as Fizz1) were highly increased in OVA-challenged WT AMs but repressed 
in OVA-challenged AQP3−/− AMs. Similarly, the expressions of genes related to chemokines, such as Ccl2, Ccl7, 
Figure 2. AQP3 is expressed on T cells, AMs, and epithelial cells. (a) mRNA expression levels of Aqp3 in 
whole lungs. Total RNA was extracted from lungs obtained from mice on day 21 (n = 3 for each group) and on 
day 28 (n = 4 for each group). Aqp3 mRNA was assessed by real-time RT-PCR. (b,c) Immunohistochemistry of 
AQP3 in the lung. Lungs of saline-challenged (n = 3) and OVA-challenged (n = 4–5) WT or AQP3−/−mice were 
dissected and stained with AQP3 antibody. Small airways (b) and alveolar spaces (c) are shown. Arrows indicate 
AMs. Bars, 10 μ m. (d) mRNA expression levels of Aqp3 in total inflammatory cells and sorted CD4+, CD8+, and 
B cells in BALF collected from OVA-challenged WT mice (n = 3 for each group).
www.nature.com/scientificreports/
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Figure 3. Impaired asthmatic airway inflammation is partly caused by decreased T cell trafficking in 
AQP3−/− mice. (a,b) Splenocytes and mesenteric lymph nodes (MLN) cells from OVA-sensitized WT and 
AQP3−/− mice were isolated on day 21 and were cultured in the presence/absence of OVA. (a) OVA-specific T 
cell proliferation assay determined by incorporation of 0.5 μ Ci/ml [3H]-thymidine for 24 h. (b) Levels of IL-4 
and IL-13 in the supernatants of splenocytes (n = 3–4 for each group). (c) Adoptive transfer experiments by 
intravenous injection. Splenocytes from OVA-sensitized donor WT and AQP3−/− mice on day 21 were injected 
intravenously (1 × 107 cells/head) to naïve recipient WT and AQP3−/− mice, then the recipient mice were 
challenged with OVA for 7 days. Numbers of total cells, eosinophils, lymphocytes and macrophages in BALF 
were determined (n = 4 for each group). (d) Adoptive transfer experiments to track transferred CD4+ T cells. 
Splenocytes from OVA-sensitized donor WT and AQP3−/− mice on day 21 were stained with CMFDA and 
injected into recipient WT mice intravenously (2 × 107 cells/head). After OVA challenge of these recipient mice, 
CD4+ and CMFDA+ cells in the thoracic lymph nodes and lungs were analyzed by flow cytometry (n = 5 for 
each group). **P < 0.01, *P < 0.05.
www.nature.com/scientificreports/
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Ccl22, and genes related to tissue remodeling, such as Igf1, Vegfa, Lyve1, F13a1, Mmp9, and Timp1, were also highly 
reduced in OVA-challenged AQP3−/− AMs compared to OVA-challenged WT AMs. The differential expressions 
of several genes were confirmed by quantitative real-time RT-PCR (Fig. 5b,c, and Supplementary Fig. S3b). 
In addition, we then measured the concentrations of those chemokines in BALF during OVA-induced airway 
inflammation. In accordance with microarray and real-time RT-PCR data for AMs, their levels were highly 
increased after OVA challenge in WT mice but were significantly suppressed in OVA-challenged AQP3−/− mice 
(Fig. 5d). Levels of pro-matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) 
in BALF were also increased after OVA challenge in WT mice but less increased in AQP3−/− mice (Fig. 5e).
Moreover, we compared the expression of overall chemokine-related genes between groups again. Besides the 
chemokines described above, several chemokines were expressed highly in OVA-challenged WT AMs compared 
to WT AMs before OVA-challenge, and their expressions were strikingly suppressed in OVA-challenged AQP3−/− 
AMs (Table 1). We measured the levels of some of these chemokines (CCL4, CCL11, CCL17, and CXCL1) in 
BALF, and confirmed that they were lower in OVA-challenged AQP3−/− mice compared to OVA-challenged WT 
mice (Supplementary Fig. S3c). We also performed immunohistochemistry for CCL11 (eotaxin-1) and CCL17 
(Thymus and activation-regulated chemokine). CCL17 was expressed in AMs in OVA-challenged WT mice, but 
not in OVA challenged AQP3−/− mice (Supplementary Fig. S4a). Although CCL17 was expressed in airway epi-
thelial cells and type 2 alveolar cells in saline-exposed WT and AQP3−/− mice, its expression was not enhanced in 
airway epithelial cells after OVA inhalation both in WT and AQP3−/− mice. We obtained almost the same results 
for CCL11 (Supplementary Fig. S4b). These findings suggest that the production of several chemokines besides 
CCL24 from AMs was impaired in OVA-challenged AQP3−/− mice, possibly due to their reduced activation.
Regulation of chemokine production by AQP3 through the amount of cellular H2O2 in M2 
polarized AMs. To determine whether M2 polarization and chemokine production were due to different 
levels of stimulation of Th2 cytokines or the dysfunction of AMs, we isolated AMs from naïve WT and AQP3−/− 
mice using FACS-Aria and stimulated them with the same levels of IL-4/13 for 24 h in vitro. As shown in Fig. 6a, 
Figure 4. The production of CCL24 is impaired in AMs from AQP3−/− mice. (a) Aqp3 mRNA expression 
levels in AMs. mRNA expression levels of Aqp3 in FACS-Aria sorted AMs (F4/80+CD11c+ cells) in 
the lungs (n = 4 for each control group; n = 6 for each OVA-challenged group). (b) Double staining of 
immunohistochemistry of AQP3 and F4/80 in the lung. Lungs of saline-challenged WT mice (left) and OVA-
challenged WT mice (right) were dissected and stained with AQP3 antibody and F4/80 antibody. Arrowheads 
indicate AMs. Bars, 10 μ m. (c) Concentrations of CCL24 in BALF on day 28 (n = 5 for each control group; n = 8 
for each OVA-challenged group). (d) Ccl24 mRNA expression levels in BALF total cells (n = 4 on day 21; n = 7 
on day 28) and AMs (n = 4 on day 21; n = 6 on day 28). **P < 0.01.
www.nature.com/scientificreports/
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Figure 5. The expressions of genes involved in chemokine, M2 polarization, and tissue remodeling are 
decreased in AMs from OVA-challenged AQP3−/− mice. (a) Heat map of genes (clusters 9 and 11) whose 
expressions were elevated after OVA-challenge in WT AMs, but not AQP3−/− AMs. Genes involved in 
chemokine, tissue remodeling, and M2 polarization are arbitrarily shown. (b) mRNA expression levels of Ccl2, 
Ccl7, and Ccl22 in AMs from OVA-challenged WT and AQP3−/− mice (n = 4 on day 21; n = 6 on day 28).  
(c) mRNA expression levels of M2 marker (Arg1 and Retnla) in AMs from OVA-challenged WT and AQP3−/− 
mice (n = 4 on day 21; n = 6 on day 28). (d) Concentrations of chemokines (CCL2, CCL7, and CCL22) in BALF 
after OVA challenge in WT and AQP3−/− mice (n = 5 for each control group; n = 8 for each OVA-challenged 
group). (e) Concentration of pro-MMP-9 and TIMP-1 in BALF after OVA challenge in WT and AQP3−/− mice 
(n = 4 for each control group; n = 7 for each OVA-challenged group). **P < 0.01, *P < 0.05.
www.nature.com/scientificreports/
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Ccl24 and Ccl22 mRNA expressions in AQP3−/− AMs were strongly suppressed after stimulation with IL-4/13 
in comparison with WT AMs. However, contrarily, Arg1 and Retnla mRNA expressions were rather increased in 
AQP3−/− AMs compared to WT AMs (Fig. 6b), suggesting that chemokine production was seemingly regulated 
by AQP3 expression not through M2 polarization.
We anticipated that AQP3 would affect chemokine production from AMs by modulating the amount 
of cellular H2O2. Firstly, we measured intracellular H2O2 levels in AMs using 5-(and-6)-chloromethyl-2′ ,7′ 
-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) fluorescence. We found that cellular H2O2 
levels were lower in naïve AQP3−/− AMs than in naïve WT AMs without and with exogenous H2O2 supplemen-
tation for 15 s (Fig. 7a). Stimulation of AMs with IL-4/13 for 24 h increased cellular H2O2 levels in both AQP3−/− 
and WT AMs, but its enhancement was more reduced in AQP3−/− AMs (Fig. 7b). Thus, AQP3 was considered to 
be involved in regulating cellular H2O2 concentration in AMs under Th2 environment.
Next, we investigated whether the amount of cellular H2O2 would influence chemokine production in AMs 
without affecting M2 polarization. We stimulated naïve WT AMs with IL-4/13 with or without 1 h pretreat-
ment with polyethylene glycol (PEG)-catalase, which decomposes hydrogen peroxide into water and oxygen. 
Pretreatment with PEG-catalase significantly suppressed an IL-4/13-induced increase in cellular H2O2 levels 
in WT AMs (Fig. 7c). Under the same condition, pretreatment with PEG-catalase significantly suppressed an 
IL-4/13-induced increase in Ccl24 and Ccl22 mRNA expressions, but not in Arg1 and Retnla mRNA expressions 
in WT AMs (Fig. 7d,e). Collectively, our results suggest that AQP3 may regulate chemokine production from M2 
polarized AMs under Th2 environment through modulating the amount of cellular H2O2.
Discussion
Here we have revealed a critical role of AQP3 in OVA-induced asthma. Our results suggest that AQP3 potentiates 
asthma through mediating T cell trafficking and chemokine production from M2 polarized AMs by regulating 
the amount of cellular H2O2. Firstly, compared to WT mice, AQP3−/− mice exhibited attenuated allergic airway 
inflammation as assessed by the number and composition of BALF cells, infiltration of inflammatory cells and 
mucus hypersecretion by histology, and Th2 cytokines in BALF. Secondly, adoptive transfer experiments demon-
strated that the transfer of sensitized AQP3−/− splenocytes had reduced airway eosinophilic inflammation due 
to impaired CD4+ T cell trafficking after OVA challenge. Thirdly, AQP3−/− mice exhibited decreased levels of 
CCL24 and some chemokines in BALF, which was consistent with their lower gene expressions in AMs from 
AQP3−/− mice than in those from WT mice. Fourthly, in vitro experiments revealed that chemokine expressions 
and intracellular H2O2 levels in Th2-cytokine-stimulated AMs were more greatly reduced in those from AQP3−/− 
mice than in those from WT mice and were decreased after PEG-catalase without changes in M2 polarization 
markers.
Chemokines play an important role at multiple levels in asthma such as leukocyte recruitment and cellular 
activation18. Characteristically, the eotaxin family works as a potent chemoattractant for eosinophils14. CCL24 
was reported to be mainly produced by AMs in murine experimental asthma14–17. We then first focused on CCL24 
and showed that AQP3 mediates its production from AMs, probably contributing to eosinophilic inflammation. 
IL-4/IL-13 induces the differentiation of AMs towards M2 macrophages, and several chemokines were reported 
to be upregulated in murine M2 macrophages3. Moreover, in addition to CCL24, the levels of CCL17 and CCL22, 
which are chemoattractants for Th2 cells, in BALF were also reduced in OVA-challenged AQP3−/− mice. Along 
with these three, some other chemokines produced by AMs were indicated to be more reduced in AQP3−/− 
mice, including CCL2, CCL7, and CCL11, which were related to asthma at different levels19–21. Additionally, M2 
macrophages are important in orchestration of tissue repair3. Microarray data and real-time RT-PCR analyses 
revealed that several genes related to tissue repair were reduced in AMs from AQP3−/− mice. We also revealed 
that levels of pro-MMP-9 and TIMP-1 in BALF in OVA-challenged AQP3−/− mice were significantly lower than 
those in WT mice. Previous studies showed that vascular endothelial growth factor, MMP-9, and TIMP-1 could 
Genbank Access Description Symbol
Level of mRNA (ratio)
WT OVA (+ ) /WT OVA (− ) WT OVA (+ ) /AQP3−/−OVA (+ )
NM_013652 chemokine (C-C motif) ligand 4 Ccl4 3.4 2.7
NM_021443 chemokine (C-C motif) ligand 8 Ccl8 44.0 4.6
NM_011338 chemokine (C-C motif) ligand 9 Ccl9 5.1 1.8
NM_011330 chemokine (C-C motif) ligand 11 Ccl11 7.3 3.1
NM_011331 chemokine (C-C motif) ligand 12 Ccl12 24.3 5.5
NM_011332 chemokine (C-C motif) ligand 17 Ccl17 12.9 1.8
NM_008176 chemokine (C-X-C motif) ligand 1 Cxcl1 2.9 5.7
NM_009141 chemokine (C-X-C motif) ligand 5 Cxcl5 7.3 2.1
AK156907 chemokine (C-X-C motif) ligand 10 Cxcl10 12.3 2.7
NM_023158 chemokine (C-X-C motif) ligand 16 Cxcl16 10.3 3.6
Table 1.  Selective list of chemokine-related genes in alveolar macrophages from OVA-challenged WT 
(WT OVA (+)) versus non-OVA-challenged WT (WT OVA (−)) or OVA-challenged AQP3−/− mice 
(AQP3−/−OVA (+)). WT, wild-type; OVA, ovalbumin. Ratio of respective mRNA is shown. Genes listed in Fig. 5a 
were not shown here.
www.nature.com/scientificreports/
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be produced by AMs and contribute to airway remodeling22,23. Thus, AQP3 may mediate asthma partly through 
regulating the production of chemokines and tissue repair-related factors from AMs.
Several studies suggested that AM is one source of the increased ROS in asthmatics24. However, how H2O2 
or ROS affects macrophage function is not well understood. Previous studies showed that H2O2 modulated the 
expression of some chemokines in rat AMs25,26 and increased mRNA of various chemokines in murine mac-
rophages by activating extracellular signal-regulated kinase- and cyclic adenosine 5-monophosphate-dependent 
pathways27. Here we focused on the effect of the cellular H2O2 level in chemokine production from WT and 
AQP3−/− AMs. Further, we found that, compared to WT AMs, the genes in the M2 marker were less upregulated 
in AQP3−/− AMs in an in vivo asthma model, but, conversely, they were more upregulated by in vitro stimulation 
with IL-4/13. We interpret this inconsistency partly due to the lower level of Th2 inflammation in AQP3−/− mice 
in vivo. We therefore considered that chemokine production from AMs was regulated by AQP3 expression possi-
bly through facilitating H2O2 uptake independently of M2 polarization.
T cell trafficking is also crucial in the pathogenesis of asthma, as recruited T cells and their products then 
mediate airway eosinophilia, mucus hypersecretion, and AHR. While T cell proliferation and activation were 
similar between OVA-sensitized WT and AQP3−/− mice during the sensitization phase, adoptive transfer experi-
ments showed that, with OVA-sensitized AQP3−/− donor splenocytes, total cells and eosinophils were reduced in 
BALF in recipient mice compared with respective results involving transferred WT donor splenocytes, suggesting 
the importance of AQP3 in airway inflammation through CD4+ T cell trafficking during the elicitation phase. 
Consistently, we reported that AQP3 facilitated chemokine-dependent T cell migration in contact hypersensitiv-
ity through mediating H2O2 transport, which was important for the activation of Cdc42 and F-actin dynamics11. 
Thus, AQP3 may be critical for T cell-mediated diseases28.
Epithelium is one of the main sources of chemokines and cytokines in asthma. Although we compared immu-
nohistochemical staining for CCL11 and CCL17 between AQP3−/− and WT mice, unlike in AMs, there was no 
difference in the expression of these chemokines in airway epithelium. We also measured the concentrations of 
Figure 6. The expression of Ccl24 and Ccl22 mRNA is impaired in IL-4/13-stimulated AMs from AQP3−/− 
mice. (a) mRNA expression levels of Ccl24 and Ccl22 in AMs in vitro. AMs isolated from naïve WT and 
AQP3−/− mice were stimulated with IL-4/13 for 24 h (n = 3 for each group). (b) mRNA expression levels of Arg1 
and Retnla in AMs stimulated with/without IL-4/13 for 24 h in vitro. **P < 0.01, *P < 0.05.
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Figure 7. AQP3 regulates chemokine production from M2 polarized AMs through affecting the amount 
of cellular H2O2. (a) H2O2 permeability in naive AMs. Sorted AMs from naïve WT and AQP3−/− mice were 
incubated with/without H2O2 (100 μ M) for 15 s. Cellular H2O2 levels were determined using CM-H2DCFDA 
reagent by flow cytometry analysis. Mean fluorescence intensity (MFI) of CM-H2DCFDA is shown (n = 3 for 
each group). (b) Intracellular H2O2 levels in IL-4/13-stimulated AMs. Sorted AMs from naïve WT and AQP3−/− 
mice were incubated with IL-4/13 for 24 h, and cellular H2O2 levels were determined (n = 4 for each group). As 
the numbers of AMs were small, we combined the results of 2 independent experiments. Ratios of MFI in each 
sample to MFI in naïve non-stimulated WT AMs are shown. (c) Cellular H2O2 levels in IL-4/13 stimulated AMs 
with/without PEG-catalase. Sorted AMs from naïve WT mice were incubated with 250 U/ml PEG-catalase for 
1 h and followed with IL-4/13 for 24 h. Cellular H2O2 levels in AMs determined using CM-H2DCFDA reagent 
(n = 4–5 for each group). (d,e) mRNA expression levels of Ccl24 and Ccl22 (d), and Arg1 and Retnla (e) in IL-
4/13 stimulated AMs with/without PEG-catalase were measured by real-time RT-PCR (n = 4 for each group). 
**P < 0.01, *P < 0.05.
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IL-33, which is mainly released from epithelial cells, in BALF and found that the levels of IL-33 were compara-
ble between AQP3−/− and WT mice (Supplementary Fig. S5). Meanwhile, B cells synthesize IgE, which affects 
the pathogenesis of allergic diseases like asthma. Serum OVA-specific IgE levels after OVA challenge were less 
increased in AQP3−/− mice than in WT mice. However, as B cells in BALF expressed Aqp3 mRNA at a very low 
level by real-time RT-PCR, this would be due to reduced IL-4 and IL-13 release from Th2 cells. Thus, we consider 
that AQP3 may not directly contribute to OVA-induced asthma through its expression on epithelium or B cells 
although further investigation is needed.
Asthma is a complex disease and interactions between various cells can play important roles29. We interpreted 
the results with adoptive transfer experiments (Fig. 3c), where eosinophilic inflammation in AQP3−/− recipient 
mice was more reduced than in comparative WT mice, by analyzing the functions of AMs. However, interactions 
of the inflammatory cells with epithelial cells, fibroblasts, endothelial cells, smooth muscle cells, etc. might also 
have affected our results in addition to the role of T cells and AMs.
Currently, asthma affects about 3 hundred million people worldwide. Its prevalence rate ranges from 1–18% in 
different countries and has been increasing in some countries30. Although inhaled corticosteroids are the main-
stay for asthma treatment, 5–10% of patients have severe asthma, which does not respond to this treatment, and 
pulmonary macrophages may have roles in this resistance31. Some mediators discussed here such as neutrophil 
chemoattractants (CXCL1, CCL7, IL-17F) and those for tissue remodeling (MMP-9 and TIMP-1) were reported 
to be related to severe asthma32–35. High-dose or long-term corticosteroids use may have some systemic side 
effects. Therefore, AQP3 may be a novel and interesting therapeutic target for severe asthma.
In conclusion, our current findings provide evidence that AQP3 mediates not only T cell trafficking but 
chemokine production of M2 polarized AMs partly through regulating the amount of cellular H2O2, in the 
OVA-induced allergic asthma model. Recent studies reported confirmation of AQP3 inhibition by gold com-
pounds36,37. Both T cells and macrophages also play a critical role in the pathogenesis of other allergic disorders 
such as allergic rhinitis and atopic dermatitis. Thus, AQP3 may represent a new therapeutic target for the treat-
ment of allergic disorders overall, including asthma.
Methods
Mice. AQP3−/− mice (C57BL/6 genetic background) were generated by targeted gene disruption38. We used 
C57BL/6 mice purchased from CLEA Japan (Tokyo, Japan) as WT control mice unless otherwise stated. All 
animal experimental protocols were approved by the Committee on Animal Research of Kyoto University, and 
performed in strict accordance with institutional guidelines.
OVA-induced murine asthma. Mice were sensitized with intraperitoneal injection (i.p.) of 50 μ g OVA 
(Sigma-Aldrich, St Louis, MO) and 1 mg alum (LSL, Tokyo, Japan) on day 0 and day 11, and then were challenged 
with aerosolized 1% OVA on days 21–27. Control mice received saline instead of OVA. Mice were sacrificed 24 h 
after the last challenge of OVA or saline (on day 28), then BALF, blood and lungs were harvested and analyzed 
(Supplementary Fig. S1a).
Bronchoalveolar lavage. The trachea was cannulated and the lung was lavaged 3 times with 1 ml of PBS 
based on the modification of our previous procedure39. The BALF was centrifuged at 1300 rpm for 10 min at 4 °C, 
and the cell pellet and supernatant were saved separately. We suspended the pellet in 5% FBS-RPMI and used an 
aliquot for counting the number of nucleated cells using a hemocytometer or flow cytometry. We cytospinned an 
aliquot of cells and stained with Diff-quick (International Reagents, Kobe, Japan), a modified simple staining of 
May-Grünwald Giemsa. We then visually performed a differential leukocyte count among at least 200 cells under 
a microscope. We also examined an aliquot of cells using flow cytometry after staining with monoclonal antibod-
ies against Thy1.2, B220, CD4, and CD8 (eBioscience, San Diego, CA).
Lung histology and immunohistochemistry. 24 h after the last challenge, lungs were distended by injec-
tion through the trachea of 10% formalin in PBS, and then were harvested. Murine lung tissues were embedded 
in paraffin and sliced into sections 4 μ m thick, which were then stained with hematoxylin and eosin, periodic 
acid–Schiff, AQP3 antibody (Millipore, Billerica, MA), CCL11, and CCL17 (R&D Systems, Minneapolis, MN).
Double staining of immunohistochemistry for AQP3 and F4/80. After deparaffinization, antigen 
retrieval treatment was performed by autoclaves in citrate buffer (pH 6.0). Then, the slides were incubated with 
a rabbit anti-mouse AQP3 antibody (dilution 1:500, Millipore), and thereafter with biotinylated anti-rabbit 
IgG antibody, followed by incubation with avidin-biotin-alkaline phosphatase complex (Vector Laboratories, 
Burlingame, CA). Color development was done with Fast red. Next, the slides were incubated with a rat 
anti-mouse F4/80 antibody (dilution 1:50, eBioscience), and thereafter with biotinylated anti-rat IgG antibody, 
followed by incubation with avidin-biotin-peroxidase complex (Vector Laboratories). Color development was 
done with 0.03% 3,3′ -diaminobenzidine tetrahydrochloride (Dojindo Laboratories, Kumamoto, Japan). Finally, 
slides were counterstained with 0.1% Mayer’s hematoxylin.
Measurement of airway resistance to methacholine. 24 h after the last challenge, airway responses 
to aerosolized methacholine (Sigma-Aldrich) were measured using the Pulmos-I system (MIPS, Osaka, Japan). 
A mouse was placed in a double-flow plethysmographic chamber and exposed to saline and increasing concen-
trations of methacholine (1.56 to 25 mg/ml) for 1 min each concentration. We then measured sRaw in conscious 
mice according to a previously reported method40,41. We maintained the same air-conditioned environment 
controlled for temperature (22 °C) and humidity (50%) during the measurements to maintain reliability and 
reproducibility.
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Measurement of OVA-specific IgE in sera. Sera were collected before OVA challenge (on day 21) and 
after the last OVA challenge (on day 28), and the levels of OVA-specific IgE were determined using an ELISA kit 
(Shibayagi, Gunma, Japan).
Cytokine and chemokine measurements. Cell-free BAL fluids or culture supernatants were analyzed 
for cytokine production. Concentrations of IL-4, IL-13, IL-17F, IFN-γ , and IL-33 were determined in a Bio-plex 
set (Bio-Rad, Richmond, CA). Concentrations of CCL24 were determined by ELISA (Raybio, Norcross, GA). 
Concentrations of CCL17 and CCL22 were determined using a MILLIPLEX MAP Mouse Cytokine/Chemokine 
Magnetic Bead panel (Millipore). Concentrations of pro-MMP-9 were determined using a MILLIPLEX MAP 
Mouse MMP Magnetic Bead panel (Millipore), and those of TIMP-1 were determined using a MILLIPLEX MAP 
Mouse Kidney Injury Magnetic Bead Panel 1 (Millipore). Concentrations of CCL2, CCL4, CCL7, CCL11, and 
CXCL1 were determined using ProcartaPlex Mouse Chemokine Panel 1 (9 plex) (eBioscience). Assays were used 
according to the respective manufacturer’s instructions.
Quantitative real-time RT-PCR. RNA was extracted with Sepasol RNA I Super (Nacalai Tesque, Kyoto, 
Japan) from lung tissues and with the RNeasy Plus Micro Kit (Qiagen, Valencia, CA) from cells. cDNA was 
reverse transcribed from total RNA samples using a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). Quantitative RT-PCR was performed using SYBR Premix Ex Taq (Takara Bio, Otsu, 
Japan) and the CFX96 real-time PCR system (Bio-Rad) according to the manufacturer’s instructions. Primers 
used in this study were shown in Supplementary Table S1.
Cell isolation from BALF. CD4+ T cells, CD8+ T cells, and B cells were isolated by positive selection using 
magnetic cell sorting (Auto-MACS) after incubating BALF cells with magnetic beads labeled with CD4, CD8, and 
CD19 (Miltenyi Biotec, Bergisch Gladbach, Germany), respectively. The Auto-MACS system (Miltenyi Biotec) 
was used in accordance with the manufacturer’s instructions.
OVA-specific cell responses. Based on our protocol for the OVA-induced asthma model shown in 
Supplementary Fig. S1a, mice were sensitized with 50 μ g OVA and 1 mg alum on days 0 and 11, and on day 21 
splenocytes and mesenteric lymph nodes cells were collected and cultured in the presence of 100 μ g/ml OVA in 
complete RPMI (RPMI 1640 supplemented with 10% heat-inactivated FBS, 50 μ M 2-mercaptoethanol (Wako, 
Osaka, Japan), 25 mM HEPES, 100 μ M nonessential amino acids, 10 μ M sodium pyruvate (Invitrogen, Carlsbad, 
CA), and 1% penicillin/streptomycin (Gibco Invitrogen, Carlsbad, CA)) for 72 h. The OVA-specific cell prolifer-
ative responses were determined by incorporation of 0.5 μ Ci/ml [3H]-thymidine for 24 h.
Adoptive transfer experiments. On day 21 after WT and AQP3−/− mice were sensitized intraperito-
neally with OVA and alum, splenocytes were collected and stimulated with 200 μ g/ml OVA in complete RPMI 
for an additional 3 days (Supplementary Fig. S1b). After stimulation with OVA, cell suspensions were intra-
venously (1 × 107 cells/head) injected to naïve WT and AQP3−/− mice. One day later, the recipient mice were 
challenged with aerosolized 1% OVA for 7 days. 24 h after the last challenge, BALF was harvested and analyzed. 
Additionally, to track the transferred cells, OVA-sensitized cells derived from WT and AQP3−/− mice were 
stained with CMFDA (Invitrogen) for 20 min, washed, and intravenously (2 × 107 cells/head) injected to naïve 
WT mice (Supplementary Fig. S1c). After the cell transfer, mice were challenged with aerosolized 1% OVA for 3 
days. Six h after the last challenge, thoracic lymph nodes and lungs were harvested, and CD4+ and CMFDA+ cells 
were analyzed by flow cytometry.
AM isolation from lungs. To obtain lung cell suspensions, we removed and minced lungs from mice. The 
minced materials were incubated in complete RPMI and collagenase A (Roche, Indianapolis, IN) for 1 h at 37 °C 
and digests were filtered through a nylon mesh (40 μ m). Dissociated cells were centrifuged at 1300 rpm for 10 min 
at 4 °C, and the cell pellet was incubated for 5 min in room air with ACK lysing buffer (Life Technologies, Grand 
Island, NY) to lyse RBCs. The single cell suspension was labeled with FITC-conjugated CD11c (eBioscience) and 
PE-conjugated F4/80 (Biolegend). AMs were sorted based on their expression of CD11c and F4/8042 by FACS 
Aria (BD Biosciences, San Jose, CA).
DNA microarray analysis. RNA was extracted from AMs of WT and AQP3−/− mice before and after the 
OVA challenge (days 21 and 28). We prepared 4–6 mice for each group and pooled their samples. Total RNA 
was converted to cDNA and was amplified using the Ovation Pico WTA System V2 (NuGen, San Carlos, CA). 
The cDNA was then labeled with Cyanine-3 using a SureTag Complete DNA Labeling Kit (Agilent, Santa Clara, 
CA). Labeled DNA was hybridized to SurePrint G3 Mouse GE 8 × 60 K Microarray (Agilent). Agilent Feature 
Extraction software was used for normalization, filtering, and initial quality control assessment of the genechip 
data. We selected 8,458 genes that differed in signal intensity both by more than 4-fold (fold change) and by a dif-
ference of more than 100 in comparison of minimum from maximum signals, and performed hierarchical cluster 
analysis on the selected genes (Supplementary Fig. S3a). Furthermore, we performed hierarchical cluster analysis 
again on 2,591 genes in clusters 9 and 11. Raw data were deposited in the Gene Expression Omnibus database: 
accession no. GSE68420.
AM culture. AMs were isolated as described above and were cultured in complete RPMI. Cells were stimu-
lated with 10 or 50 ng/ml IL-4 and IL-13 for 24 h to induce M2 macrophages. For some experiments, cells were 
pretreated with 250 units/ml PEG-catalase (Sigma-Aldrich) for 1 h before the culture.
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H2O2 permeability assay. Cellular H2O2 was assayed using the CM-H2DCFDA reagent (Invitrogen) 
according to the manufacturer’s instructions.
Statistical analysis. We made comparisons among data with either the Student’s t test or analysis of vari-
ance. We considered P values of less than 0.05 to be statistically significant.
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